Literature DB >> 2884899

Halothane selectively attenuates alpha 2-adrenoceptor mediated vasoconstriction, in vivo and in vitro.

D R Larach, H G Schuler, J A Derr, M G Larach, F A Hensley, R Zelis.   

Abstract

The mechanism by which halothane interferes with catecholamine-induced vasoconstriction was examined, utilizing specific agonists at postjunctional alpha 1- and alpha 2-adrenoceptors on vascular smooth muscle. Stimulation of either adrenoceptor subtype normally produces vasoconstriction. Two experimental models of drug-induced vasoconstriction were used: in vivo blood pressure response in pithed rats, and in vitro isometric tension development in canine saphenous vein rings. These models were then utilized to examine the anti-vasoconstriction properties of halothane. In vivo, halothane (1 MAC) produced a significant depression in the vascular response to azepexole (an alpha 2-adrenoceptor agonist), but halothane did not alter vasoconstriction by phenylephrine (an alpha 1-adrenoceptor agonist). Halothane caused a 24% reduction of maximal response (P less than 0.0001) to azepexole in pithed rats, and a 3.2-fold rightward shift of the log dose-response curve (P less than 0.0001). Similarly, in vitro, halothane significantly attenuated alpha 2- but not alpha 1-adrenoceptor responsiveness. Halothane (4%) depressed maximal vein contraction to azepexole by 26% (P less than 0.0001), and shifted the log concentration-response curve 2.4-fold to the right (P less than 0.0001). The observed selective interference with alpha 2-mediated vasoconstriction by halothane is unlikely to represent drug antagonism at the receptor level. Our observations may suggest, indirectly, that halothane interferes with Ca+2 entry into vascular smooth muscle. The phenomenon of selective anti-vasoconstriction at alpha 2-adrenoceptors by halothane may explain why alpha 1-adrenergic agonists often appear to retain their vasopressor activity during halothane anesthesia. The mechanism of halothane-induced vasodilation thus includes attenuation of alpha 2- but not alpha 1-adrenergic vasoconstriction; this further demonstrates the multifactorial nature of halothane-induced vasodilation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2884899     DOI: 10.1097/00000542-198706000-00012

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

1.  Halothane anaesthesia does not modify the cardiovascular response to phenylephrine in man.

Authors:  D F Grum; S S Azmy
Journal:  Can J Anaesth       Date:  1990-11       Impact factor: 5.063

2.  Comparison of changes in the extracellular concentration of noradrenaline in rat frontal cortex induced by sibutramine or d-amphetamine: modulation by alpha2-adrenoceptors.

Authors:  K E Wortley; Z A Hughes; D J Heal; S C Stanford
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

3.  Halothane inhibits the pressor effect of diphenyleneiodonium.

Authors:  Y X Wang; C C Pang
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

4.  Enhancement of pressor response to intravenous phenylephrine following oral clonidine medication in awake and anaesthetized patients.

Authors:  S Inomata; T Nishikawa; S Kihara; Y Akiyoshi
Journal:  Can J Anaesth       Date:  1995-02       Impact factor: 5.063

5.  Does propranolol alter the vascular response to phenylephrine before or during halothane anaesthesia in patients with coronary artery disease?

Authors:  D F Grum; S S Azmy
Journal:  Can J Anaesth       Date:  1992-01       Impact factor: 5.063

6.  Halothane and isoflurane preferentially inhibit prostanoid-induced vasoconstriction of rat aorta.

Authors:  M Yamamoto; Y Hatano; M Kakuyama; H Hirakata; H Toda; N Seo; M Nishiwada; K Nakamura; K Mori
Journal:  Can J Anaesth       Date:  1994-10       Impact factor: 5.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.